Related Experiment Videos
Post-Marketing Nutrivigilance of Red Yeast Rice-Containing Food Supplements: Spontaneous Adverse Event Reports and
Arrigo Francesco Giuseppe Cicero1,2, Federica Fogacci1,3,4
1Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, 40130 Bologna, Italy.
Abstract:
Background and Objectives: Red yeast rice (RYR)-containing food supplements are widely used for mild-to-moderate hypercholesterolemia, but their post-marketing safety remains relevant. This study characterized their safety profile within a structured multicompany nutrivigilance framework. Methods: Spontaneous reports of suspected adverse events (AEs) associated with RYR-containing food supplements were collected between 12 December 2022 and 31 May 2024. Cases were documented using a structured case report form, medically reviewed, and classified for causality according to the World Health Organization-Uppsala Monitoring Centre framework. Exposure was estimated from cumulative manufacturing and sales data. Results: A total of 148 AE reports were collected from 12 European countries. Estimated exposure corresponded to 608,815 exposed subject-periods over 18 months, based on cumulative manufacturing and sales data and recommended daily dosage. Mean age was 65.3 ± 13.3 years; among reports with available age, 58.1% occurred in individuals aged ≥70 years. Gastrointestinal events were most frequent (45.9%), followed by arthromyalgia (16.9%) and hypersensitivity reactions (10.8%). Most events were mild or moderate (97.9%); severe and serious events accounted for 0.7% and 1.4%, respectively. Both serious AEs occurred in individuals aged ≥70 years. The estimated exposure-based reporting rate was 0.02% for all AEs and 0.0003% for serious AEs. Conclusions: Within a structured post-marketing nutrivigilance framework, RYR-containing food supplements showed a low reporting frequency of AEs relative to estimated exposure, with most events being mild or moderate. Future research should strengthen harmonized nutrivigilance systems and integrate product-specific exposure data, formulation characteristics, and post-marketing safety monitoring to support more precise risk assessment.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Toxicity: Risk factors
Drug Toxicity: Allergic Reactions
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drug toxicity: Idiosyncratic Reactions